AbbVie and Janssen present progress in dermatology at AAD

19 February 2018

Major players in the dermatology space have been showing off their latest data at the American Academy of Dermatology (AAD) Annual Meeting.

US drugmaker AbbVie (NYSE: ABBV) has made two major presentations, the first from two Phase III psoriasis trials of risankizumab, an investigational interleukin-23 (IL-23) inhibitor being developed in a collaboration with privately-held German pharma major Boehringer Ingelheim.

The ultIMMa-1 and ultIMMa-2 replicate clinical trials evaluated the safety and efficacy of risankizumab (150mg) compared to placebo or Janssen’s Stelara (ustekinumab) (45 or 90mg, based on patient weight).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK